The initial public offering (IPO) palooza continued into October with two more filings, including one by Karyopharm Therapeutics Inc. seeking to raise up to $80 million. Karyopharm’s S-1 was filed just two months after the biotech closed a $19 million Series B extension that propelled its venture financing to $97.2 million.